Anbio Biotechnology balance sheet

At the end of fiscal 2025, Anbio Biotechnology had total assets of $30.2m, total liabilities of $87,836 and shareholders' equity of $30.2m. It held $7.8m in cash against $0 of debt: net cash of $7.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anbio Biotechnology: balance sheet, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	7	10	12	8
Receivables	—	2	1	4
Total current assets	—	16	19	30
Total assets	—	16	19	30
Accounts payable	—	1	2	0
Total current liabilities	—	1	2	0
Total debt	0	0	0	0
Total liabilities	—	1	2	0
Shareholders' equity	13	15	17	30
Net debt (negative = net cash)	−7	−10	−12	−8

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NNNN vs NUWE MLSS vs NNNN NMTC vs NNNN NNNN vs XAIR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anbio Biotechnology's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Anbio Biotechnology.